We report the proceedings of the First International new-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES) Symposium. To promote awareness of this condition and foster research efforts, we conveyed the First International new-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES) Symposium. The conference was supported by The NORSE Institute http://www.norseinstitute.org). This article summarizes the discussions that were held during the Symposium and presents our strategy to unravel the cause of these disorders and to improve patient care. The standardized definitions for these disorders that have been developed, are required to improve communication and facilitate the development of multicenter registries and biobanks. A distinction between childhood-and adult-onset forms of the syndrome is not supported by strong scientific evidence and it is argued that both should be studied together. Although the pathophysiology remains elusive, nascent evidence suggests a role for a post-infectious cytokine-mediated mechanism, which should be further investigated. It also appears important to develop tools for their early recognition and prompt treatment. Recent evidence suggests that specific electroencephalography (EEG) features might be helpful. The optimal treatment options remain to be determined; immune therapies are usually disappointing, but the ketogenic diet has proved effective in uncontrolled trials. NORSE and FIRES represent a very delicate clinical situation with specific communication issues between physicians and with patients and families. Standardized consensus definitions and a multidisciplinary multicenter strategy will help research efforts and improve clinical care for patients with NORSE and FIRES.
NORSE Versus FIRES: What's in a Name?
Commentary Nearly 60 years ago, sudden-onset refractory status epilepticus following a minor febrile illness in previously healthy children was identified (1) . Since then, multiple series of similarly affected children have been described, bearing different names for this syndrome, including devastating epilepsy in school-age children, acute nonherpetic encephalitis with refractory repetitive partial seizures, acute encephalitis with refractory repetitive partial seizures, and fever-induced refractory epileptic encephalopathy (FIRES) (2) . This syndrome has come to be known most consistently as febrile infection-related epilepsy syndrome (FIRES) (3). Consistent patterns of presentation, seizure types, and outcome have been identified. The status epilepticus is typically followed by intractable multifocal epilepsy without an intervening quiescent period and there are severe neurologic sequelae (4). Mandatory diagnostic criteria were suggested, including acute onset of seizures in the absence of underlying developmental delay or prior unprovoked seizures, refractory focal status epilepticus necessitating long-term anesthesia, followed by refractory epilepsy. Antecedent febrile illness, no specific MRI abnormalities, and CSF with a mild pleocytosis, increase in protein, or upregulated inflammatory markers are supportive findings (5) . Although fever, inflammation, and infection are theorized to play a part in this syndrome, no clear cause has been found (4).
A similar entity in adults was also described in 2005. These original patients were noted to be female, without significant past medical or psychiatric history, all presented with seizure followed by refractory multifocal status epilepticus without an identifiable cause. Only two of the seven patients survived, and those were described as being in a vegetative state with ongoing daily seizures (6) .
Subsequently, there has been debate regarding whether this represents one syndrome, multiple syndromes, and what the name(s) should be. In general, FIRES was felt to occur in children and was more reliably associated with a febrile illness (3, 4) . However, onset without a preceding febrile illness has been reported (7). New-onset refractory status epilepticus (NORSE) has been described in adults and fever is not apparent in all, although it is often a preceding symptom (6, 8) . Furthermore, Ismail and Kossoff (2) performed an extensive review of the literature and determined the patients in all the case reports were phenotypically similar, regardless of the name, concluding all nomenclatures reflect the same entity.
All of which causes one to ask the questions: How important is it to define FIRES and NORSE, or determine whether they are truly the same disease? Does this change the outcome of this terrible diagnosis? Should I care? The answer to all three is Yes.
Epilepsy syndrome diagnosis has been identified as an important method of communication between providers since the 1960s. According to a recent International League Against Epilepsy position paper on classification of the epilepsies, epilepsy classification is "the key clinical tool in evaluating an individual who is presenting with seizures" (9) . If providers can accurately identify an epilepsy syndrome, they will have a better understanding of cause, treatment, and prognosis, as well as comorbidities (9) . FIRES and NORSE present suddenly, violently, in previously healthy individuals with catastrophic outcomes. Therefore, being able to counsel families about expected outcomes allows families to make more informed decisions regarding proposed treatment plans. Most importantly, identification of a specific syndrome provides much needed answers and closure for families. Wong explained this eloquently in the recent NORSE commentary, in which she stated: "Just as scientists need consensus definitions around which to organize their thinking and research, families need to know what hurt their loved ones. Without a name, there is no closure. Knowing the name of the disorder allows families to find a community in which to share their grief, pool their knowledge, and to direct their actions and their resources. "
How, then, do we settle the debate between FIRES and NORSE? Are they separate or the same entity? According to the recent definitions, both are correct. Furthermore, the concept of new onset refractory status epilepticus has been better delineated. Specifically, NORSE is identified now as a clinical presentation, rather than a disease diagnosis, in a patient without preceding neurologic disease, or clear acute cause. Due to variability in diagnostic capabilities between medical centers, and to avoid potential treatment delays, patients determined to have viral or autoimmune encephalitis can still be considered to have NORSE. Furthermore, patients with a remote history of brain injuries and resolved epilepsy can also have NORSE.
In essence, if a patient presents with completely unexpected refractory status epilepticus without retained awareness, they have NORSE. Those with unknown etiology after comprehensive evaluation can later be classified as a subgroup of NORSE of unknown etiology. Not all patients need to have super-refractory status epilepticus. This is also a separate subgroup. Furthermore, FIRES is now considered to be a subgroup of NORSE that is associated with a febrile illness prior to onset, but not necessarily at the time of onset of the status epilepticus. FIRES can occur at any age.
Are these definitions too broad? The inclusion of patients with a prior history of resolved epilepsy, as well as those later determined to have viral or autoimmune encephalitis is certainly broader than the previous proposed diagnostic criteria (5) . However, the overall course of recurrent seizures that are profoundly refractory to multiple medications, followed by intractable epilepsy without a latent period and significant neurological sequelae is a consistent finding. Furthermore, the new proposed consensus of definitions appropriately points out that NORSE is not a typical or expected presentation for viral or autoimmune encephalitis and the direct causal role is unclear. Finally, this more updated definition of NORSE is more consistent with the definition of an epilepsy syndrome. According to the most recent ILAE classification of the epilepsies, an epilepsy syndrome incorporates seizure types, EEG, imaging, triggers, and comorbidities. There is not a specific correlation with etiology (9) . Therefore, NORSE is consistent with other epileptic encephalopathies, such as West Syndrome or Lennox Gastaut Syndrome, with variable etiologies. However, regardless of etiology, expected outcomes and preferred treatments have been identified for these syndromes. This information comes only through studying large populations of similarly affected patients. By more clearly defining NORSE as an electroclinical syndrome of variable etiology and with multiple subcategories, the hope is that we can finally collect adequate data to allow us to better determine effective treatments for this devastating syndrome.
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